| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg |
|
||
| 1g | |||
| Other Sizes |
| Targets |
Xanthine oxidoreductase-IN-5 targets xanthine oxidoreductase (XOR). XOR is the enzyme responsible for the final steps of uric acid production, catalyzing the oxidation of hypoxanthine to xanthine and xanthine to uric acid. Inhibition of XOR reduces serum uric acid levels. The compound's potent inhibition makes it valuable for studying hyperuricemia.
|
|---|---|
| ln Vitro |
In vitro, Xanthine oxidoreductase-IN-5 inhibits XOR with an IC50 of 55 nM. This demonstrates potent enzyme inhibition in biochemical assays, supporting its potential for studying hyperuricemia and related metabolic disorders.
|
| ln Vivo |
Xanthine oxidoreductase-IN-5 (compound IIIa) (5 mg/kg; Syrian drug) showed an effect on reducing uric acid in acute hyperuricemic allergic reactions after 5 h [1].
In vivo, Xanthine oxidoreductase-IN-5 (Compound IIIa) at 5 mg/kg (oral) showed a uric acid-lowering effect in acute hyperuricemic mice at 5 hours after administration. It may be used in studies of acute hyperuricemia and for evaluating potential therapeutic strategies for gout. |
| Enzyme Assay |
XOR activity is measured using spectrophotometric assays. The enzyme is incubated with xanthine substrate in the presence of Xanthine oxidoreductase-IN-5 at varying concentrations. Uric acid production is measured by absorbance at 290 nm, and IC50 values are calculated from dose-response curves.
|
| Cell Assay |
The cellular activity of Xanthine oxidoreductase-IN-5 is evaluated in cellular models of uric acid production. Cells are treated with the compound, and uric acid levels in the culture medium are measured to assess XOR inhibition. Hepatocyte models are commonly used for these studies.
|
| Animal Protocol |
Animal/Disease Models: ICR mice (18 -22 g) were induced with acute hyperuricemia by injecting potassium oxonate and hypoxanthine [1]
Doses: 5 mg/kg Route of Administration: suspended in 0.5% CMC-Na solution The result of intragastric (po) (po) Route of Administration: the uric acid-lowering effect was shown after 5 hrs (hrs (hours)). In vivo efficacy is evaluated in an acute hyperuricemia mouse model induced by potassium oxazinate/hypoxanthine. Mice are administered the compound orally at 5 mg/kg, and serum uric acid levels are measured at various time points. |
| ADME/Pharmacokinetics |
Xanthine oxidoreductase-IN-5 has a molecular formula of C17H17N5O2 and a molecular weight of 323.35 g/mol. The compound is orally active. It is stored under recommended conditions.
|
| Toxicity/Toxicokinetics |
Comprehensive toxicological data for Xanthine oxidoreductase-IN-5 are limited. The compound is intended for research use only. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
Xanthine oxidoreductase-IN-5 (Compound IIIa) is an orally active XOR inhibitor (IC50 = 55 nM). It can be used for research on acute hyperuricemia and is a valuable tool for studying uric acid metabolism and potential therapeutic interventions for gout and related conditions.
|
| Molecular Formula |
C17H17N5O2
|
|---|---|
| Molecular Weight |
323.349182844162
|
| Exact Mass |
323.14
|
| Elemental Analysis |
C, 63.15; H, 5.30; N, 21.66; O, 9.90
|
| CAS # |
1026652-90-3
|
| PubChem CID |
11255758
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
2.7
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
24
|
| Complexity |
404
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(C)OC1=CC=C(C=C1)NC(=O)C2=CC=C(C=C2)C3=NNN=N3
|
| InChi Key |
OTVAJNZWRVQKOM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H17N5O2/c1-11(2)24-15-9-7-14(8-10-15)18-17(23)13-5-3-12(4-6-13)16-19-21-22-20-16/h3-11H,1-2H3,(H,18,23)(H,19,20,21,22)
|
| Chemical Name |
N-(4-isopropoxyphenyl)-4-(2H-tetrazol-5-yl)benzamide
|
| Synonyms |
Xanthine Oxidoreductase-IN-5; CS-0626928
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0926 mL | 15.4631 mL | 30.9262 mL | |
| 5 mM | 0.6185 mL | 3.0926 mL | 6.1852 mL | |
| 10 mM | 0.3093 mL | 1.5463 mL | 3.0926 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
